SPDR S&P Pharmaceuticals ETF
XPH
XPH
71 hedge funds and large institutions have $98.4M invested in SPDR S&P Pharmaceuticals ETF in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
38% less call options, than puts
Call options by funds: $834K | Put options by funds: $1.35M
Holders
71
Holding in Top 10
–
Calls
$834K
Puts
$1.35M
Top Buyers
| 1 | +$4.48M | |
| 2 | +$2.22M | |
| 3 | +$1.06M | |
| 4 |
GS
GTS Securities
New York
|
+$812K |
| 5 |
Goldman Sachs
New York
|
+$646K |
Top Sellers
| 1 | -$10.4M | |
| 2 | -$5.92M | |
| 3 | -$4.44M | |
| 4 |
Jane Street
New York
|
-$2.32M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.28M |